Guggenheim analyst Brad Canino raised the firm’s price target on Nuvalent (NUVL) to $155 from $125 and keeps a Buy rating on the shares. The positive neladalkib pivotal data lead the firm to “fully de-risk” its second-to-third line ALK+ NSCLC odds of success estimate and increase its first-line odds to 75%, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL: